Answers are grounded in this paper and cite their sources.
Research demonstrates USP34's role in reducing cartilage degradation in temporomandibular joint osteoarthritis, suggesting new treatment approaches.
The pain and dysfunction caused by temporomandibular joint osteoarthritis (TMJ OA) can be debilitating. However, effective disease-modifying medicine for TMJ OA remains an unfulfilled need. While progressive cartilage degradation represents the hallmark of TMJ OA, the underlying molecular mechanisms remain incompletely understood. Here, we identify USP34 as a key regulator of mitochondrial quality control in TMJ chondrocytes through its stabilization of adenine nucleotide translocase 1 (ANT1). Using chondrocyte-specific Usp34 knockout (Usp34icKO) mice, we first demonstrated age-dependent TMJ OA development characterized by cartilage destruction. Subsequent unilateral bite-raising (UBR) experiments revealed that USP34 deficiency exacerbated mechanical stress-induced TMJ degeneration. Our results disclosed the dual protective role of USP34 against both age-related and mechanical stress-related TMJ degeneration. Mechanistically, we define the USP34-ANT1 axis as a component upstream of the PINK1-Parkin pathway. USP34 deubiquitinates and stabilizes ANT1, thereby promoting the initiation of Parkin-dependent mitophagy. Additionally, USP34 overexpression confers protection to chondrocytes against cellular injury. These findings establish USP34 as a critical node linking ubiquitin signaling to mitochondrial homeostasis in TMJ chondrocytes and propose targeting USP34 or ANT1 as a potential disease-modifying strategy.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: